Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000569775 | SCV000676043 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-11-22 | criteria provided, single submitter | clinical testing | The c.1667+1delG intronic variant results from a deletion of G one nucleotide after coding exon 14 of the MLH1 gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNA decay. The exact functional effect of the altered amino acid sequence is unknown. This variant has been identified in a proband who met Amsterdam I criteria for Lynch syndrome and had a colon polyp that demonstrated loss of both MLH1/PMS2 expression by immunohistochemistry (IHC) (Ambry internal data). This variant has also been previously reported in an individual diagnosed with colorectal cancer at age 20 that showed loss of PMS2 expression by IHC and family history met Amsterdam II criteria for Lynch syndrome (Jansen AM et al. PLoS One, 2016 Jun;11:e0157381; van der Klift HM et al. Mol Genet Genomic Med 2015 Jul;3(4):327-45). RNA studies have demonstrated that this variant results in the inclusion of an 87 base pair intronic sequence predicted to result in an in-frame insertion of 29 amino acids in the protein (van der Klift HM et al. Mol Genet Genomic Med 2015 Jul;3(4):327-45; Jansen AM et al. PLoS One, 2016 Jun;11:e0157381; Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Baylor Genetics | RCV004568231 | SCV005057947 | likely pathogenic | Colorectal cancer, hereditary nonpolyposis, type 2 | 2024-03-25 | criteria provided, single submitter | clinical testing |